DB:6RC

Stock Analysis Report

Executive Summary

ReproCELL Incorporated operates as a stem cell research company in Japan.


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has ReproCELL's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 6RC's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

23.8%

6RC

11.7%

DE Biotechs

9.9%

DE Market


1 Year Return

62.4%

6RC

-8.1%

DE Biotechs

-17.5%

DE Market

Return vs Industry: 6RC exceeded the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: 6RC exceeded the German Market which returned -17.7% over the past year.


Shareholder returns

6RCIndustryMarket
7 Day23.8%11.7%9.9%
30 Day22.8%-5.9%-16.6%
90 Day76.6%-22.6%-24.8%
1 Year62.4%62.4%-7.9%-8.1%-15.0%-17.5%
3 Year-7.9%-7.9%16.6%15.4%-17.4%-24.5%
5 Year-40.6%-40.6%-6.1%-8.5%-16.6%-28.1%

Price Volatility Vs. Market

How volatile is ReproCELL's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is ReproCELL undervalued compared to its fair value and its price relative to the market?

4.06x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 6RC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 6RC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 6RC is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 6RC is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6RC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6RC is overvalued based on its PB Ratio (4.4x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is ReproCELL forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

33.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 6RC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 6RC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 6RC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 6RC's revenue (32.6% per year) is forecast to grow faster than the German market (4.1% per year).

High Growth Revenue: 6RC's revenue (32.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 6RC's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has ReproCELL performed over the past 5 years?

-5.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 6RC is currently unprofitable.

Growing Profit Margin: 6RC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 6RC is unprofitable, and losses have increased over the past 5 years at a rate of -5.8% per year.

Accelerating Growth: Unable to compare 6RC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6RC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: 6RC has a negative Return on Equity (-12.93%), as it is currently unprofitable.


Next Steps

Financial Health

How is ReproCELL's financial position?


Financial Position Analysis

Short Term Liabilities: 6RC's short term assets (¥5.9B) exceed its short term liabilities (¥344.0M).

Long Term Liabilities: 6RC's short term assets (¥5.9B) exceed its long term liabilities (¥89.0M).


Debt to Equity History and Analysis

Debt Level: 6RC's debt to equity ratio (1.2%) is considered satisfactory.

Reducing Debt: 6RC's debt to equity ratio has reduced from 3.7% to 1.2% over the past 5 years.


Balance Sheet

Inventory Level: 6RC has a low level of unsold assets or inventory.

Debt Coverage by Assets: 6RC's debt is covered by short term assets (assets are 74.1x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6RC has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: 6RC has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -12.3% each year


Next Steps

Dividend

What is ReproCELL's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6RC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 6RC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6RC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6RC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 6RC's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

11.7yrs

Average board tenure


CEO

Chikafumi Yokoyama (51yo)

14.25s

Tenure

Dr. Chikafumi Yokoyama, Ph.D serves as the Chief Executive Officer of ReproCELL, Inc. and has been its President since November 2005. Dr. Yokoyama joined ReproCELL Inc. in 2004 as General Manager of Busine ...


Board Members

NamePositionTenureCompensationOwnership
Chikafumi Yokoyama
President and Representative Director14.25yrsno data1.33% ¥3.0m
Daisuke Usui
Chief Financial Officer and Directorno datano data0.025% ¥55.9k
Yoshiyuki Yamakawa
External Director11.67yrsno datano data
Masahiro Suzuki
External Standing Corporate Auditor8yrsno datano data
Yukari Sakai
External Auditor11.67yrsno datano data
Akira Ishikawa
External Auditor7.67yrsno datano data

11.7yrs

Average Tenure

52yo

Average Age

Experienced Board: 6RC's board of directors are seasoned and experienced ( 11.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.8%.


Top Shareholders

Company Information

ReproCELL Incorporated's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ReproCELL Incorporated
  • Ticker: 6RC
  • Exchange: DB
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: JP¥26.206b
  • Listing Market Cap: JP¥221.629m
  • Shares outstanding: 71.41m
  • Website: https://www.reprocell.com

Number of Employees


Location

  • ReproCELL Incorporated
  • MetLife Shin-Yokohama 381 Building
  • 9th Floor
  • Yokohama
  • Kanagawa
  • 222-0033
  • Japan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4978JASDAQ (TSE JASDAQ)YesCommon StockJPJPYJun 2013
6RCDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2013

Biography

ReproCELL Incorporated operates as a stem cell research company in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, pluripotent stem cell culture media, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, and feeder cells; and 3D cell culture, labware, and drug discovery assays. The company also provides stem cell services, such as target cell isolation, iPSC reprogramming, and cell differentiation, as well as iPSC expansion, characterization, and banking services; and predictive drug discovery services in the areas of cardiac, vascular, respiratory, gastrointestinal, ADME/DMPK, skin/skin model, genitourinary, comparative pharmacology, and other assays. In addition, it offers human tissue samples, prospective collections, molecular, 3D cell, primary cell isolation, and DNA and RNA extraction services. ReproCELL Incorporated was founded in 2003 and is headquartered in Yokohama, Japan. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/31 22:46
End of Day Share Price2020/03/31 00:00
Earnings2019/12/31
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.